Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute Discusses Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial At The 60th ASH Annual Meeting on Dec 1, 2018.
The Future Of Elotuzumab In 2019
